Kevin Kunzmann

A clinical trial from Norway showed inconclusive results, and challenges in the study design.

Data show an enhanced, auditory alert driving simulator may reduce distraction and inconsistent driving among teenagers with ADHD.

A study from China shows women receiving laparoscopic surgery had better sleep quality in the days after when receiving the treatment as an intraoperative prophylactic.

As we begin our annual health care recap series this month, let's take a look back at the stories our readers liked most.

Brett King, MD, PhD, reviews how the drug class has altered the state of chronic skin disease management in this year alone.

Why patience is key following the major FDA decision earlier this year.

New long-term phase 3 data show adults and adolescents both improved measures of quality of life when treated with either of 2 doses of ruxolitinib cream.

Findings from the ongoing LIBERTY AD OLE trial show the sustained long-term effect of the biologic therapy for eczema.

Online survey results show adults with psoriasis in specific areas may be treating and monitoring disease without clinician guidance—sometimes out of embarassment.

Long-term, real-world data show the IL-23 inhibitor benefits patient-reported measures of psychological wellbeing.

New data show adults receiving the biologic for eczema may see improvements in sleep disturbance within 4 weeks.

Post hoc analysis data from JADE REGIMEN show continuous and reduced-dose regimens provided similar efficacy and safety outcomes in the 2 age groups.

Phase 3 data suggest the novel twice-daily drug provides favorable efficacy and consistent safety over a regular regimen in patients aged 12 years and older.

Phase 3 data suggest children aged <6 months to 5 years old have benefit in itch relief and skin clearance as soon as 1 week into systemic therapy regimens.

New data from ECZTRA 1 and 2 show patients unable to achieve complete skin clearance nonetheless benefitted in at least 1 component of disease improvement.

Patients with psoriasis in high-impact areas may benefit from either of 2 available dosing regimens of the biologic.

Despite a Boxed Warning included in its 2017 FDA approval, the plaque psoriasis biologic was not linked to any causal cases of suicide attempts in 4-year, real-world data.

The pair of pulmonology and microbiology experts join the podcast to discuss what clinicians should look out for in indoor pollutant exposure risks, and how to manage their impact.

An online survey of adult patients shows a strong desire for a singular, consistent topical option.

New registry analysis shows persistent treatment with the IL-23 improved disease in patients predominately with a history of past biologic therapies.

New pooled phase 3 data presented at ACAAI 2022 supports the FDA's approval of dupilumab for eosinophilic esophagitis.

Will the complement C5 inhibitor drug receive FDA approval in 2023? Lally discusses this and more on the latest DocTalk.

David R. Lally, MD, reviews the duration and patient demographic data of the investigative drug.

A review of the development of complement inhibitors and how the latest GATHER2 data support avacincaptad pegol for the treatment of geographic atrophy.

A retrospective comparative trial showed that agents including bevacizumab, ranibizumab and aflibercept are linked to similar likelihood of RPE tears.

New phase 2 data show a synthetic, proprietary 25 mg dose from COMPASS may fare better for adult patients than a 10 mg dose.

An analysis of over-the-counter products show not all AMD-targeting supplements match the recommended dosage from the National Institutes of Health.

New cohort analysis data suggest the risk of COVID-19 death is about 38% decreased among patients with the autoimmune disease.

New phase 3 data shared at Fall Clinical Dermatology show the IL-13 inhibitor maintained skin clearance observed at 16 weeks.

After the announced recall of dry shampoo products by Unilever this month, dermatologists anticipate an uptick in patient concerns.